✨ Free AI Report
Nurix Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Nurix Therapeutics, Inc.
Company Research

Nurix Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Nurix Therapeutics is advancing a multi-modal pipeline using targeted protein degradation to harness the cell's natural protein degradation machinery for treating cancers and autoimmune diseases. The company maintains...

Analyst-debate audio for Nurix Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Nurix Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Clinical-stage biotech with pioneering protein degradation platform, strong pharma partnerships, and growing market validation in...

Read the full analyst-debate transcript →
Industry Biopharmaceutical/Targeted Protein Degradation Therapeutics
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Nurix Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Nurix Therapeutics, Inc. Overview

Pro stress-test →

Nurix Therapeutics is advancing a multi-modal pipeline using targeted protein degradation to harness the cell's natural protein degradation machinery for treating cancers and autoimmune diseases. The company maintains strategic collaborations with Gilead Sciences, Sanofi, and Pfizer for co-development and co-commercialization of multiple drug candidates.

Strategic Profile

Pro stress-test →

Nurix utilizes an integrated discovery platform incorporating artificial intelligence and ligase expertise to support research activities. The company develops Degrader Antibody Conjugates (DACs) that combine the cell specificity of antibodies with the potency and selectivity of degraders. Recent significant funding of $250 million and recognition as a high-potential small cap stock indicate strong financial backing and market confidence.

Competitive Landscape

Pro stress-test →

Omeros, AC Immune, Cullgen, Fate Therapeutics, and Alzinova represent some of 33 competitors in the targeted protein degradation and biopharmaceutical space. Nurix's differentiation centers on its proprietary DELigase platform, established pharma partnerships, and clinical validation of multiple degrader modalities across oncology and immunology indications.

Industry Context

Nurix Therapeutics, Inc. operates in Biopharmaceutical/Targeted Protein Degradation Therapeutics.

Key facts

Founded: 2009 · Headquarters: San Francisco, CA · Employees: 201-500 · Revenue: $84M · Market cap: $1.7B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Nurix Therapeutics, Inc..

  • Lead candidate Bexobrutideg (NX-5948) is in Phase 1B/2 trials targeting B-cell malignancies and autoimmune diseases.
  • Gilead Sciences extended its strategic collaboration research term for an additional two years with a $15 million extension fee and future milestone eligibility.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025Presented positive Phase 1 trial data for Bexobrutideg in CLL patients at ASH Meeting
  • October 2025Closed $250 million registered offering of common stock
  • +2 moreTrack every material event for Nurix Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Nurix Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Targeted Protein DegradationClinical-stage protein degradation therapeutics→Targeted Protein DegradationE3 ligase modulators for drug discovery→Antibody-Drug ConjugatesOncology-focused biopharmaceutical company→Immuno-oncologyBiopharmaceutical company in Seattle→

Compare Nurix Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Nurix Therapeutics, Inc. operates in Biopharmaceutical/Targeted Protein Degradation Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical/Targeted Protein Degradation Therapeutics research →
NEW · MCP server

Ask your AI assistant about Nurix Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Nurix Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Nurix Therapeutics, Inc. do this quarter?”
“Is Nurix Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Nurix Therapeutics, Inc. do?+
Nurix Therapeutics is advancing a multi-modal pipeline using targeted protein degradation to harness the cell's natural protein degradation machinery for treating cancers and autoimmune diseases. The company maintains...
What is Nurix Therapeutics, Inc.'s Cyborg Score?+
Nurix Therapeutics, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Nurix Therapeutics, Inc.'s main competitors?+
Named competitors include Targeted Protein Degradation, Targeted Protein Degradation, Antibody-Drug Conjugates, Immuno-oncology. The full competitive landscape is in the AskCyborg report.
How can I get the full Nurix Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Nurix Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Nurix Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score